Mylan NV’s (MYL.O) largest stakeholder, Abbott Laboratories (ABT.N), said it would back Mylan’s proposed acquisition of Perrigo Co Plc (PRGO.N), potentially helping Mylan fend off interest from Teva Pharmaceutical Industries Ltd (TEVA.TA).
Abbott, which has a 14.5 percent stake in Mylan, said on Tuesday that it supported Mylan’s “standalone strategy” and believed acquiring Perrigo would add value for shareholders.
Mylan’s latest offer for Perrigo, worth $34.1 billion, is widely seen as an attempt to fend off Teva, the world’s biggest maker of generic drugs.
Help employers find you! Check out all the jobs and post your resume.